Which statement correctly reflects Beers Criteria regarding dual RAS blockade in CKD stage 3a or higher?

Which statement correctly reflects Beers Criteria regarding dual RAS blockade in CKD stage 3a or higher?

• A. Avoid routinely using two RAS inhibitors or a RAS inhibitor with a potassium-sparing diuretic
• B. Routinely combine two RAS inhibitors for better kidney protection
• C. Only one RAS inhibitor is allowed, regardless of CKD stage
• D. Dual blockade is recommended in CKD stage 1 only

Answer: (A)

Dual RAS blockade means using two inhibitors that affect the renin-angiotensin system, such as an ACE inhibitor plus an ARB, or adding a potassium-sparing diuretic with a RAS blocker. The Beers Criteria advises against this approach in older adults with CKD stage 3a or higher because the combination does not provide additional kidney protection and markedly increases the risk of adverse effects, especially hyperkalemia and acute kidney injury, along with potential hypotension. The lack of proven extra benefit, coupled with these safety concerns, makes routine dual blockade inappropriate in this setting. While there may be rare, carefully monitored circumstances where a clinician might consider altering therapy, the general guidance is to avoid routinely combining two RAS inhibitors or adding a potassium-sparing diuretic in CKD stage 3a or higher. The other statements misstate the guidance or imply routine use in stages where it isn’t supported, which is why they’re not correct.

Dual RAS blockade means using two inhibitors that affect the renin-angiotensin system, such as an ACE inhibitor plus an ARB, or adding a potassium-sparing diuretic with a RAS blocker. The Beers Criteria advises against this approach in older adults with CKD stage 3a or higher because the combination does not provide additional kidney protection and markedly increases the risk of adverse effects, especially hyperkalemia and acute kidney injury, along with potential hypotension. The lack of proven extra benefit, coupled with these safety concerns, makes routine dual blockade inappropriate in this setting. While there may be rare, carefully monitored circumstances where a clinician might consider altering therapy, the general guidance is to avoid routinely combining two RAS inhibitors or adding a potassium-sparing diuretic in CKD stage 3a or higher. The other statements misstate the guidance or imply routine use in stages where it isn’t supported, which is why they’re not correct.